Neurology Journal Club: Characteristics and Outcomes of Patients With IDH-Mutant Grade 2 and 3 Gliomas After Deferred or Adjuvant Radiotherapy.

Authors

Kimberly Wang, Jordan L Smith, Anh Huan Vo, Lindsey Sloan, Lawrence R Kleinberg, Sushant Puri

Published in

Neurology. Volume 107. Issue 9. Pages e218666. Nov 10, 2026. Epub Oct 08, 2026.

Abstract

This journal club article reviews the strengths and limitations of a 2025 study by Lanman et al., investigating outcomes-particularly overall survival-in patients with isocitrate dehydrogenase mutant (IDHmt) WHO grade 2 and 3 gliomas who received either adjuvant postsurgical radiotherapy (aXRT) or deferred radiotherapy (dXRT). Despite unclear evidence of survival benefit, current standardized guidelines recommend aXRT-after surgery but before progression-as first-line treatment for high-risk patients defined by higher grade, older age, and subtotal resection. This study demonstrated that although aXRT delayed tumor progression in this cohort, it was associated with worse overall survival. This retrospective, dual-institution analysis highlights a discrepancy between current guidelines and real-world clinical outcomes, emphasizing the need for prospective studies evaluating dXRT in patients with IDH-mutant gliomas.

PMID:
42848969
Bibliographic data and abstract were imported from PubMed on 09 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.